TNFSF13B and systemic lupus erythematosus: Only one of the two phase III clinical trials of tabalumab, a fully human monoclonal antibody that targets soluble and membrane-bound BAFF, met its primary endpoint, i.e., proportion of patients achieving SRI-5 at week 52 (92, 93), and no further development of this drug was therefore planned for SLE.